Stockwinners Market Radar for May 12, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:12 EDT Cathie Wood's ARK Investment bought 240.8K shares of Coinbase today

19:06 EDT Lockheed Martin awarded $129.0M U.S. Army contract modification - Lockheed Martin was awarded a $129,040,507 modification to contract W56KGY-21-C-0010 for the purchase of six radar systems, spares, tool kits, remote computer display units, integrated computer systems, training, contractor technical assistance, field service representatives, software support and program management. Work will be performed in Syracuse, New York, with an estimated completion date of Aug. 11, 2026.

18:45 EDT Micron CEO: Our end markets are well diversified - In an interview on CNBC's Mad Money, Sanjay Mehrotra said demand trends are secular in Micron's end markets. He is confident in the company's demand drivers and its execution. Micron is number one in automotive and industrial IOT, he noted. The company is an "innovation powerhouse," with 50,000 patents, he added. Enterprise and desktop PCs continue to be a "healthy market" for Micron.

18:23 EDT Affirm CEO: Our underlying business is performing very well - In an interview on CNBC's Mad Money Max Levchin said the consumer is alive and well. "They are shopping, buying, and paying their loans quite well," he added. "We are in fact as good as we say we are." Customers like Affirm's honesty with credit and that is why they come back, he noted. Changing rates have not had any impact on the company's costs. "Our cost of capital is just fine," he said.

17:20 EDT Alpha & Omega to replace Mimecast in S&P 600 at open on 5/19

17:19 EDT Dynavax to replace Bottomline Technologies in S&P 600 at open on 5/17 - Thoma Bravo LP is acquiring Bottomline Technologies in a deal expected to be completed on May 13.

16:57 EDT Robinhood surges 36% to nearly $12 after FTX CEO takes stake

16:54 EDT CymaBay expects cash to fund operations through 2023 - The company said, "Held $193.4 million in cash, cash equivalents and investments as of March 31, 2022. We believe that cash and investments on hand, together with committed capital available through the development financing agreement with Abingworth, is sufficient to fund CymaBay's operating plan through 2023."

16:44 EDT Toast jumps 8% to $15.40 after raising FY22 guidance

16:40 EDT Houlihan Lokey enters new buyback program for up to $500M in common stock - The Board of Directors replaced its prior stock repurchase program, which authorized repurchases from time to time up to $250 million in aggregate purchase price of the Company's common stock, with a new stock repurchase program, which authorizes repurchases of an aggregate of up to $500 million of the Company's common stock.

16:40 EDT Houlihan Lokey raises quarterly dividend to 53c from 43c per share - The dividend will be payable on June 15, 2022 to stockholders of record as of the close of business on June 2, 2022.

16:37 EDT Molecular Templates sees cash, investments funding operations to end of 2023

16:34 EDT Motus GI Holdings expects cash balance to fund operations through Q1 2023 - The Company reported $20.3 million in cash and cash equivalents as of March 31, 2022. This balance includes the fully funded $12.0 million credit facility with Kreos Capital. The Company's current cash balance allows it to continue executing on its upcoming catalysts and is expected to meet overall anticipated cash needs into Q1 2023.

16:33 EDT West Pharmaceutical announces executive leadership appointments - West Pharmaceutical appointed CFO Bernard Birkett to a newly combined position of Chief Financial and Operations Officer. The company's Senior VP, Chief Global Operations and Supply Chain Officer, David Montecalvo has announced his resignation to pursue other interests with a departure of July to ensure a seamless transition. West's Senior VP, Global Markets and Commercial Solutions, Cindy Reiss-Clark, has been appointed to the role of Chief Commercial Officer. Additionally, West's Senior VP, Commercial Products and Emerging Markets, Chris Ryan has been appointed to Senior VP, Containment and Glass Systems. The Company has also hired Kathy dePadua as VP and Chief Quality Officer. dePadua joins West from GE Healthcare where she most recently held the position of Global Quality Executive for the Life Care Solutions Strategic business unit.

16:30 EDT Compass announces changes to executive structure and strategic plan - Compass CFO Kristen Ankerbrandt will be leaving Compass in September to pursue opportunities outside the company. Additionally, Chief Product Officer Greg Hart has been promoted to the role of COO. Ankerbrandt joined Compass in 2018. Ankerbrandt will continue in the role of CFO through September. Compass has initiated a search for a permanent CFO. The company has retained an international executive search firm to lead the search. Both internal and external candidates will be evaluated. Hart joined Compass in April of 2020, after 23 years at Amazon being involved in all aspects of product development, product and general management, marketing, content, and e-commerce. Joseph Sirosh will continue in his role as the Chief Technology Officer, leading engineering, AI and Enterprise Technology, and continue to report to Compass Founder, Chairman and CEO Robert Reffkin.

16:29 EDT Salarius Pharmaceuticals announces estimated cash runway extends into 2023 - Cash and cash equivalents totaled $24.2 million on March 31, 2022; $2.3 million direct offering with institutional investors closed on April 26, 2022; Estimated cash runway extends into 2023.

16:28 EDT MeridianLink board authorizes $75M share buyback - The board of directors has authorized a new stock repurchase program to acquire up to $75M of the company's common stock. The program is effective immediately.

16:27 EDT Siga Technologies awarded $7.5M Department of Defense contract - SIGA Technologies announced that the U.S. Department of Defense awarded a contract to SIGA for the procurement of up to approximately $7.5M of oral TPOXX, of which approximately $3.6M of oral TPOXX is targeted for delivery in 2022 and the remainder is subject to an option at the sole discretion of the DoD.

16:26 EDT Vincerx Pharma expects cash to fund operations through 2023 - Vincerx Pharma had $96.5 million in cash as of March 31, 2022, as compared to $111.5 million as of December 31, 2021. Based on its current business plans and assumptions, Vincerx believes its available cash will be sufficient to meet its operating requirements through 2023.

16:24 EDT One Liberty Properties acquires Georgia industrial building for $17M - One Liberty Properties announced that it acquired a 213,000 square foot industrial building located in Dalton, Georgia for $17.0M. The property is leased through mid-2032 to Q.E.P. Co., a manufacturer and distributor of flooring and installation solutions for commercial and home applications. The net lease provides for an annual base rent of approximately $883,000 with annual increases of 3.0% beginning in 2023. The Class B facility, which was constructed in 1996, has good access to I-75, is located between Chattanooga and Atlanta, features 24-foot through 31-foot clear heights in the warehouse and 25 loading-dock doors. The company anticipates it will obtain $10M of ten-year mortgage debt, at an interest rate of 3.50% and amortizing over 30 years, on this property.

16:23 EDT KKR acquires five self-storage properties for roughly $98M - KKR announced the acquisition of five new self-storage properties totaling approximately 4,100 units for an aggregate purchase price of approximately $98 million. The properties were acquired from four different sellers in three separate transactions and are located in: Phoenix, Arizona; Dallas, Texas; San Antonio, Texas; and Palm City, Florida. "We continue to expand our portfolio of high-quality self-storage properties across Sunbelt markets that are experiencing strong population growth and in-migration," said Ben Brudney, a Director in the Real Estate group at KKR. "We track sector fundamentals closely and believe these assets are located in submarkets that are well positioned to benefit from outsized demand over the medium to long term." The purchases were made through KKR's Americas opportunistic equity real estate fund, KKR Real Estate Partners Americas III.

16:20 EDT Aurora Cannabis raises expense savings target to C$150M-C$170M - Now expects C$150M-C$170M in Annualized cost savings by H1/2023 versus stated target of C$60M-C$80M. "We continue to steer our differentiated global cannabis business towards long term shareholder value creation. This is being accomplished through a sole focus on the most profitable growth opportunities, rationalization of our Canadian cost structure and disciplined use of capital. Our plan is working and we remain firmly on track to achieving a positive Adjusted EBITDA run rate by the first half of fiscal 2023. Today, we are announcing further cost savings which will enable us to increase our range of savings under our business transformation plan from $60 to $80 million to $150 to $170 million. Our balance sheet also remains among the strongest in the industry, enabling the repurchase of $141.4 million in convertible debt early, while also providing meaningful working capital to support organic growth and pursue strategic M&A, such as our recent acquisition of Thrive Cannabis," stated Miguel Martin, CEO of Aurora.

16:16 EDT Figs reports active customers up 31.1% to 2M at March 31 - Net revenues per active customer was $226, an increase of 6.1% year over year. Average Order Value was $116, an increase of 16.0% year over year primarily driven by a higher mix of lifestyle products, which result in higher units per transaction and generally have a higher price point.

16:13 EDT Penske Automotive raises share repurchase program to $250M - From January 1 through April 30, the company had repurchased 1.9M shares for $184.1M, leaving it with $46.3M available as of April 30.

16:12 EDT Penske Automotive raises quarterly dividend 6.4% to 50c per share - The dividend is payable June 1 to shareholders of record on May 23.

16:11 EDT Union Pacific raises quarterly dividend 10% to $1.30 per share - The dividend is payable June 30 to shareholders of record May 31.

16:09 EDT Fiesta Restaurant sees restaurant-level adjusted EBITDA margin 18%-20% - The company said: "First quarter 2022 Restaurant-level Adjusted EBITDA margins, a non-GAAP financial measure, improved to 16.1% compared to 14.3% in the fourth quarter of 2021. Following the 5.0% pricing taken in early March, estimated Restaurant-level Adjusted EBITDA margins grew to above 17.0% on a run-rate basis. We continue to target Restaurant-level Adjusted EBITDA margin of 18.0% to 20.0% as our sales growth and labor optimization initiatives increasingly gain momentum."

16:08 EDT Erasca announces upcoming milestones - HERKULES-1: Initial Phase 1b monotherapy data expected in second half of 2022. HERKULES-3: Initial Phase 1b combination data expected between the fourth quarter of 2022 and the first half of 2023. FLAGSHP-1: Initial Phase 1 monotherapy data expected in second half of 2022; Initial Phase 1b combination data in triple wildtype CRC expected between the fourth quarter of 2022 and the first half of 2023. ERAS-3490: IND filing expected in second half of 2022

16:03 EDT Equillium sees cash, investments funding operations for at least next 12 months

14:58 EDT Poxel treatment of X-Linked Adrenoleukodystrophy granted orphan status - A treatment of X-Linked Adrenoleukodystrophy being developed by Poxel S.A. was granted orphan designation by the FDA, according to a post to the agency's website. Reference Link

14:35 EDT Coinbase seeing recovery from account access issues - Coinbase said it is seeing recovery after implementing a fix for issues customers have had today with trading and accessing accounts. The company noted, however, that its teams are continuing to monitor the situation. "Rest assured, we have all hands on deck and will continue our work to ensure our services are healthy," Coinbase tweeted. Reference Link

14:12 EDT Micron to raise dividend to 11.5c from 10c per share - On May 12, at its Investor Day presentation, Micron Technology announced its intention to increase its quarterly dividend from 10c per share of outstanding company common stock to 11.5c per share of outstanding company common stock.

13:00 EDT Everest Re raises quarterly dividend to $1.65 per share from $1.55 - Everest Re announced that its Board of Directors declared an increase in the regular quarterly dividend from $1.55 to $1.65 per common share. This dividend will be payable on or before June 17, 2022 to all shareholders of record as of May 25, 2022.

13:00 EDT COVID-related supply disruption offset by digital presence, Petros CCO says

13:00 EDT Petros CCO sees 'significant prospects' being first mover in ED as OTC option

12:19 EDT TNON Stock trading resumes

12:14 EDT TNON Stock trading halted, volatility trading pause

12:00 EDT Jazz to present data from oncology portfolio at ASCO and EHA - Jazz Pharmaceuticals announced that the company and its partners will present seven abstracts at the American Society of Clinical Oncology, or ASCO, Annual Meeting from June 3-June 7 and eight abstracts at the 27th Annual Congress of the European Hematology Association, or EHA, from June 9-12. Research findings to be presented include data on Rylaze/JZP458, Zepzelca, Defitelio and Vyxeos/Vyxeos Liposomal, also known as JZP351. "As part of Jazz's commitment to explore potential new applications of our oncology medicines to address critical needs, we continue to advance programs that could impact difficult-to-treat therapeutic areas. Our growing, early-stage pipeline, combined with ongoing Jazz-sponsored and partner research across our portfolio, is making significant progress when it comes to addressing unmet patient needs in cancers that have historically lacked scientific advancements," said Rob Iannone, M.D., M.S.C.E., executive vice president, global head of research and development of Jazz Pharmaceuticals.

12:00 EDT Dutch Bros falls -28.4% - Dutch Bros is down -28.4%, or -$9.77 to $24.61.

12:00 EDT Coupang rises 24.8% - Coupang is up 24.8%, or $2.40 to $12.07.

12:00 EDT Siemens to exit Russian market as a result of Ukraine war - Siemens released a statement on the war in Ukraine and on the situation in Russia: "We join the international community in condemning the war in Ukraine and are focused on supporting our people and providing humanitarian aid. Siemens will exit the Russian market as a result of the Ukraine war. The company has started proceedings to wind down its industrial operations and all industrial business activities. Siemens was one of the first companies to put all new business in and international deliveries to Russia on hold while it evaluated the situation to ensure the safety of its 3,000 employees in the country."

11:47 EDT Microsoft's Bethesda delays Xbox games 'Starfield,' 'Redfall' to 2023 - Bethesda, which is owned by Microsoft, announced that it is delaying the launches of upcoming Xbox and PC games "Starfield" and "Redfall" to the first half of 2023. Both games were originally scheduled for late 2022 releases. "The teams at Arkane Austin (Redfall) and Bethesda Game Studioes (Starfield) have incredible ambitions for their games, and we want to ensure that you receive the best, most polished versions of them," Bethesda said in a statement posted to Twitter. Reference Link

11:37 EDT International Paper general counsel Sharon Ryan to retire, Joe Saab to succeed - International Paper announced that Sharon Ryan, Senior Vice President, General Counsel and Corporate Secretary, will retire effective June 30, 2022. Ryan joined the Company in 1988 and was elected Senior Vice President, General Counsel and Corporate Secretary in 2011 Joseph Saab has been elected Senior Vice President, General Counsel and Corporate Secretary effective July 1, 2022. Saab joined the Company in 2001 as legal counsel for Environment, Health and Safety. In 2019, he was appointed Vice President, Deputy General Counsel and Assistant Corporate Secretary and his recent responsibilities have included Enterprise Corporate Law and Operational Excellence, as well as overseeing support for and advising the Board of Directors.

11:19 EDT SoundHound AI Inc trading halted, volatility trading pause

11:05 EDT GameStop, AMC, Bed Bath & Beyond rise as 'meme stocks' see momentum - Shares of GameStop (GME) are up $16.68, or 20%, to $98.01 in morning trading while AMC Entertainment (AMC) has gained 15% and Bed Bath & Beyond (BBBY) is up 10% as this trio of "meme stocks" and other names favored in the past by retail traders are seeing renewed upward pressure.

10:47 EDT MorphoSys to present new data on Pelabresib and Monjuvi at EHA and ASCO - MorphoSys AG announced that new data on pelabresib and tafasitamab, marketed in the U.S. as Monjuvi and in Europe as Minjuvi, will be presented during the 2022 American Society of Clinical Oncology Annual Meeting, or ASCO 2022, in Chicago from June 3-7 and the 2022 European Hematology Association Hybrid Congress, or EHA 2022, in Vienna, Austria, from June 9-12. "The data presented at this year's EHA and ASCO congresses showcase the breadth, depth and potential of our growing pipeline of cancer medicines. At EHA 2022, we're excited to be presenting the latest results from the ongoing Phase 2 MANIFEST trial. These data suggest the potential of pelabresib, if approved, to change the current standard of care in the first-line treatment of myelofibrosis, a difficult-to-treat bone marrow cancer for which only limited treatment options are available. Further, at ASCO 2022, we will present new data from the RE-MIND2 study. This trial is using real world data to investigate the potentially prolonged survival benefit tafasitamab may offer to patients living with relapsed or refractory diffuse large B-cell lymphoma, an aggressive and debilitating disease," said Malte Peters, M.D., MorphoSys Chief Research and Development Officer.

10:41 EDT Theseus Pharmaceuticals Inc trading resumes

10:36 EDT Theseus Pharmaceuticals Inc trading halted, volatility trading pause

10:19 EDT GameStop trading resumes

10:14 EDT GameStop trading halted, volatility trading pause

10:12 EDT Corus Entertainment enters partnership with Alexandra Gater - Corus Entertainment's creator agency Kin Community Canada and Nelvana have come together to launch a 360-degree partnership across social, television, streaming and merchandising with home decor expert and Kin creator Alexandra Gater. One of Canada's top home & DIY YouTubers, Gater is an editor, stylist and home decor expert focused on showing millennials how to live in a home that feels stylish and beautiful, even if you rent. She joined the Kin roster in 2018 and witnessing the strength, timeliness and popularity of her content and brand, Corus is extending its partnership with Gater to expand her brand into new areas and platforms.

10:08 EDT Motorola Solutions acquires Videotec, terms not disclosed - Motorola Solutions announced it has acquired Videotec S.p.A., a global provider of ruggedized video security solutions based in Italy. Videotec's fixed and Pan, Tilt and Zoom cameras are designed to withstand the extreme conditions and hazardous environments of critical infrastructure, specifically ports, energy and transportation, where video security is imperative. Videotec's portfolio enables security operators to have clear visibility across these settings to quickly detect and respond to abnormal events or dangerous situations, reducing safety threats and supporting business continuity. The acquisition of Videotec complements Motorola Solutions' line of fixed video cameras, expanding its portfolio and reinforcing the company's position as a global leader in video security solutions. Terms of the transaction were not disclosed.

10:04 EDT Jasper County, Texas streamlines budgeting operations with Questica solutions - Questica announced that Jasper County, TX is implementing Questica solutions to support its immediate and future budgeting processes.

10:03 EDT Global Blood Therapeutics announces data presentations on Sickle Cell Disease - Global Blood Therapeutics announced five abstracts related to its sickle cell disease programs will be presented at the European Hematology Association 2022 Hybrid Congress. Presentations include new real-world evidence data on Oxbryta as well as an oral presentation of additional data from the Phase 1 study of GBT021601, the company's next generation sickle hemoglobin polymerization inhibitor. In addition, initial findings from the Sickle Cell Health Awareness, Perspectives and Experiences survey, a global burden of disease study assessing healthcare professional, patient and caregiver perspectives on the unmet needs in SCD, will be presented at the Congress, which will be held from June 9-12 in Vienna, Austria and online. Following are highlights of GBT's presentations at the Congress. Data from a large retrospective study of 216 patients in the United States treated with Oxbryta in a real-world setting further supports its utility in treating patients with SCD: New data from the multicenter Retrospective Study to Evaluate Outcomes in Patients with Sickle Cell Disease Treated with Oxbryta provide further support that treatment with Oxbryta is associated with increased hemoglobin levels and decreased hemolytic markers. These data are consistent with those from the Phase 3 HOPE Study that led to the approval of Oxbryta. Data from the Phase 1 studies of GBT601, which has shown promise in the clinic, supports its further development: Multiple daily doses of GBT601 were well tolerated in both healthy volunteers and adult SCD patients. In SCD patients, the 100 mg maintenance dose studied resulted in a mean Hb occupancy of more than 30%, increased Hb levels, reduced markers of hemolysis, and improved red blood cell health. Additional data will be included with the oral presentation. Data presented from two abstracts add greater insight into the disease burden and effect of Hb levels on people with SCD: The multinational Sickle Cell Health Awareness, Perspectives and Experiences Survey assessed HCP perspectives on treating SCD and the patient burden of the disease. Results of the SHAPE survey underscore the negative impact of SCD on quality of life and highlight health inequities in SCD and the need for improved awareness, education and treatments that fully address end-organ damage in SCD. A retrospective analysis of 12 years of data from the Clinical Practice Research Datalink and the Hospital Episode Statistics databases in the UK was sufficient to observe end-organ damage events in patients with SCD. It showed that an increase in Hb of 1 g/dL was associated with a significant reduction in the risk for stroke, pulmonary hypertension, chronic kidney disease, end-stage renal disease, leg ulcers, and pneumonia, supporting the use of therapeutics that increase Hb levels in patients with SCD to protect against organ damage. A presentation on GBT's pivotal Phase 3 studies of inclacumab, the company's P-selectin inhibitor: Currently in progress and enrolling patients, the two pivotal Phase 3 THRIVE studies are evaluating the safety and efficacy of inclacumab in reducing vaso-occlusive crises and readmissions due to VOCs. An additional THRIVE open-label expansion study will examine the long-term safety of inclacumab in individuals with SCD.

10:02 EDT Raytheon Technologies announces strategic investment in Hermeus - Raytheon Technologies announced a strategic investment in Hermeus Corporation, a company developing hypersonic aircraft for defense and commercial applications, through its newly established corporate venture capital group, RTX Ventures. Joining Hermeus' previously announced $100 million Series B financing round, RTX Ventures' investment in the company will directly support the buildout of its first aircraft, Quarterhorse, and accelerate development of its next aircraft, Darkhorse. "Hypersonic technologies are of critical importance to national security, which is why we made our first investment in a company with such a bold plan and vision in this space. Hermeus' technical approach and business plan balances near-term defense applications with long-term commercial aspirations and will help our customers reimagine the possibilities of hypersonic technologies," said Daniel Ateya, managing director of RTX Ventures.

10:00 EDT Silvergate Capital falls -14.1% - Silvergate Capital is down -14.1%, or -$10.05 to $61.46.

10:00 EDT Dutch Bros falls -40.1% - Dutch Bros is down -40.1%, or -$13.79 to $20.58.

10:00 EDT Bowlero rises 8.8% - Bowlero is up 8.8%, or 73c to $9.00.

09:49 EDT Carvana trading resumes

09:47 EDT Beyond Meat trading resumes

09:47 EDT Solo Brands falls -15.0% - Solo Brands is down -15.0%, or -76c to $4.32.

09:47 EDT Traeger rises 10.8% - Traeger is up 10.8%, or 47c to $4.88.

09:47 EDT Squarespace rises 20.5% - Squarespace is up 20.5%, or $2.96 to $17.39.

09:43 EDT Carvana trading halted, volatility trading pause

09:42 EDT Unity Software trading halted, volatility trading pause

09:42 EDT Solo Brands Inc trading resumes

09:38 EDT SAI.TECH Global Corp trading resumes

09:37 EDT Solo Brands Inc trading halted, volatility trading pause

09:35 EDT Willamette Valley Vineyards trading resumes

09:31 EDT Six Flags trading halted, volatility trading pause

09:31 EDT Fluence Energy trading halted, volatility trading pause

09:30 EDT NVX Stock trading halted, volatility trading pause

09:28 EDT Mynaric, Airbus U.S. Space & Defense sign contract fo laser communication demo - Mynaric and Airbus U.S. Space & Defense, Inc. have signed a contract to host Mynaric's CONDOR Mk2 terminal for space-based laser communication on the International Space Station's functional testbed, Bartolomeo. Mynaric plans to operate its industrialized optical communications terminal on the ISS, with the goal of demonstrating the product's capabilities in low Earth orbit and providing its customers with an extended range of experimental mission scenarios. The terminal will be hosted on the Airbus built and operated Bartolomeo External Payload and Science Hosting Facility attached to the European Space Agency's Columbus laboratory . Bartolomeo serves as a functional testbed on the ISS that enables a wide range of customers the opportunity to test and mature emerging technologies and innovative solutions to expand terrestrial and space economies. The CONDOR's positioning on Bartolomeo will provide it a clear view of Earth and space, allowing Mynaric to offer its customers excellent conditions to test and demonstrate a range of laser communication use cases involving a space-based terminal compliant, amongst others, with the Space Development Agency's optical communications interoperability standard . As part of this on-orbit demonstration, Mynaric plans to put its CONDOR optical communications terminal through a rigorous test regime demonstrating various capabilities and building operational heritage in space.

09:24 EDT Greenpro Capital, Cryptosx create crypto exchange in Malaysia - As recently announced, the Malaysian Government has given Greenpro Capital the License to operate a Digital Assets Exchange in Labuan, Malaysia. With this new license in mind, Greenpro Capital, and through its group company First Bullion Holdings Inc. who is the company behind CryptoSx will build and operate the world's first Shariah-compliant exchange. This exchange will facilitate the monetization of assets currently not available for Public Investment. Creating the first exchange of its' kind, Greenpro expects to capitalize on a previously nearly untapped market of the ASEAN Regions. This Exchange will be onboarding and facilitating the trading of Tokens, Stable Coins, and other Digitized Assets. Priority and focus will be given to assets that are in line with ESG and carbon free principles. Greenpro and First Bullion will, with Greenpro's connections to high net worth individuals and the governments of the ASEAN region, facilitate the creation of Stable coins predicated on assets such as real estate, minerals, currencies, government debt, and many other types of hard assets. Greenpro, of course, welcomes everyone to list their Tokens, Coins, and Assets on this new exchange, as long as the structure is compliant with Shariah Law and is ESG Compliant.

09:22 EDT Focus Financial announces $200M share repurchase authorization - Focus Financial Partners announced that its Board of Directors approved a share repurchase program to repurchase up to $200 million of the Company's Class A common stock from time to time in the open market, in privately negotiated transactons, or by such other means as will comply with applicable state and federal securities laws.

09:17 EDT Skye Bioscience signs arrangement agreement with Emerald Health Therapeutics - Skye Bioscience (SKYE) and Emerald Health Therapeutics (EMHTF) announced that the companies have entered into a definitive agreement with respect to a transaction to be completed by way of a Plan of Arrangement whereby Skye would acquire all of the issued and outstanding shares of Emerald in a share-for-share-transaction. Emerald possesses cash and non-cash assets that Skye would acquire through the Arrangement. As a result of the Arrangement, current Skye stockholders would own approximately 54% of the common stock of Skye and former shareholders of Emerald would own approximately 46% of Skye's common stock. Under the Arrangement, Skye will issue Emerald shareholders 1.95 shares of Skye's common stock in exchange for each Emerald share. Based on the number of outstanding shares as of the date of this press release, it is expected that Skye would issue approximately 416M Skye shares to Emerald shareholders. The Arrangement is anticipated to close in the third quarter of 2022. Upon completion of the transaction, the combined company would continue to operate under the name Skye Bioscience, Inc. with its existing management team. Sukhwinder Rai, BSc. Biochem, BSc. Pharm, RPh., from Emerald's Board of Directors would join Skye's Board of Directors. "Skye's proposed acquisition of Emerald stands to strengthen its balance sheet and ability to advance its well-positioned technology and development platform that has generated promising preclinical data in the past year and a half. Despite the constraints of COVID on all facets of the life science industry, Skye has completed the preclinical preparation necessary to launch its first-in-human study of its lead drug, SBI-100 OE, in the second quarter of 2022. We expect regulatory approval to start our Phase 1 study and begin enrolling patients shortly. The transaction with Emerald is expected to provide funding into 2023 and, importantly, for our planned Phase 2 study starting in the fourth quarter of 2022," said Praveen Tyle, Ph.D., Chair of the Board's Special Committee of Skye Bioscience and President, CEO.

09:15 EDT WWE names Suzette Ramirez-Carr Chief Human Resources Officer - WWE announced that Suzette Ramirez-Carr has been named Chief Human Resources Officer, reporting to Chairman & CEO Vince McMahon. Ramirez-Carr brings to WWE nearly three decades of executive experience, including senior positions with United Talent Agency, Beautycounter and Oaktree Capital Management. During her tenure, she led the Human Resources, DEI , Facilities and Internal Communications functions.

09:14 EDT Zealand Pharma sees FY22 net operating expenses DKK $1B plus or minus 10% - On March 30, 2022 Zealand updated the guidance for net product revenue from the sales of commercial products to be DKK 115 million +/- 10%. This was a decrease of 120 million Danish kroner from the guidance issued on March 10, 2022. Combined sales of V-Go and Zegalogue in Q1 were 39.2 million Danish kroner and in line with the updated guidance. Following the company's announced intent to exit its V-Go activities, net product revenue for the device is to be accounted for as discontinued operations and no longer reported as net product revenue. As such, net product revenue reported in the Q1 earnings release only reflects sales of Zegalogue, which were 4.1 million Danish kroner with full year net product revenue projected to be 19 million Danish kroner excluding any potential partnerships or licensing agreements. In 2022, Zealand Pharma expects revenue from existing license agreements. However, since such revenue is uncertain in terms of size and timing, Zealand Pharma does not intend to provide guidance on such revenue. Net operating expenses in 2022 are expected to be DKK 1,000 million +/-10%. This is unchanged from our updated guidance issued on March 30, 2022 and is a decrease of DKK 200 million from the guidance issued on March 10, 2022.

09:14 EDT Global Ship Lease announces participation in carbon capture initiative - Global Ship Lease announced its participation in a carbon capture initiative led by Aqualung Carbon Capture ASL. George Youroukos, Executive Chairman of Global Ship Lease, commented, "Maritime regulators, our liner customers, and the general public increasingly recognize, as do we, that decarbonization of the shipping sector is an imperative that demands immediate action. The challenges are significant. One of the biggest is for the shipping industry to adapt to what is likely to be a non-standardized, multi-fuel environment in the future - with each fuel type requiring its own infrastructure, propulsion technology, safety protocols, training, and all else that such a fundamental shift entails. In contrast, if the container shipping industry teaches us anything, it is that standardization can unlock a virtuous cycle, reducing costs and facilitating and accelerating the buildout of support infrastructure and services. This is one of the things that makes carbon capture so compelling: almost regardless of the initial fuel input, the ultimate output is a highly standardized and well understood carbon dioxide molecule. While our financial commitment is limited, we are pleased to have found, in Aqualung, a carbon capture technology with great potential and a team - supported by the right combination of strategic investors - that is highly focused on both practicality and scalability. Crucially, we believe that such a technology can play a central role in extending the lives of existing ships, by significantly mitigating their emissions and increasing their competitiveness in an increasingly carbon-regulated environment, which is a key step, in our view, in transitioning to a decarbonized future."

09:13 EDT Archer Daniels to invest to expand starch production at Minnesota facility - ADM announced it will invest to significantly expand starch production at its Marshall, Minnesota, facility in order to meet fast-growing demand from the food and beverage sectors, and to support the continued expansion of the company's BioSolutions platform. The Marshall project is expected to be complete in the second half of 2023.

09:11 EDT Ingevity publishes environmental product declaration for Evotherm WMA - Ingevity Corporation announced an environmental product declaration was published for its Evotherm M1 Warm Mix Asphalt technology. The Evotherm M1 EPD distinguishes Ingevity as the first chemical additive supplier to be included in the National Asphalt Pavement Association's Emerald Eco-Label tool that provides supply chain-specific upstream environmental data for asphalt mixtures. The EPD for Evotherm M1 denotes Ingevity's compliance with environmental impact assessment standards for manufacture of the warm mix additive by measuring and reporting the cradle-to-gate impacts of manufacturing and packaging, and assessing the material, energy, waste and emissions impacts of processing and transporting the raw additive materials. A prior study conducted by consulting firm ERM, London, U.K., determined that the use of Evotherm M1 warm mix asphalt additive offsets the volume of greenhouse gases generated in its manufacture by a factor range of 18 to 23. The Emerald Eco-Label tool is a web-based software program that allows asphalt mixture producers to develop verified plant-specific and mix-specific EPDs that quantify the environmental impacts of the asphalt mixtures, helping asphalt producers assist their customers in meeting their environmental goals. Integrating Ingevity's EPD for Evotherm M1 into the Emerald Eco-Label tool provides upstream data for asphalt mixtures that contain Evotherm M1.

09:09 EDT LKQ Corp. announces $500M increase in stock repurchase program - LKQ announced that its Board of Directors has authorized a $500M increase to its existing stock repurchase program. This raises the aggregate program authorization to $2.5B through October 25, 2024. Since initiating the stock repurchase plan in October 2018, the Company has repurchased 37.3M shares through March 31, 2022 for total consideration of approximately $1.5B. Varun Laroyia, Executive Vice President and Chief Financial Officer of LKQ Corporation, stated: "The strength of the balance sheet and our expectations for continued free cash flow generation have the Company well positioned to execute on the expanded stock repurchase program. The strong financial metrics and the expansion of this program further validate our commitment to a disciplined capital allocation strategy that balances returning capital to our stockholders and investing in the continued growth of the Company."

09:09 EDT Maxeon Solar and lphaESS partner for residential clean energy solutions - Maxeon Solar and AlphaESS, an energy storage solution and service provider, have entered into a global strategic partnership to develop integrated clean energy solutions for residential customers. The partnership combines AlphaESS' power conversion and storage solutions and technology services with Maxeon's solar panel technology and global go-to-market channel comprising a partner network of more than 1,400 installers and resellers in over 100 countries. The goal is to develop and deliver integrated solutions and advanced services.

09:08 EDT CohBar announces extension of Nasdaq compliance period - CohBar announced that The Nasdaq Capital Market has granted the Company's request for a 180 day extension, or until November 7, 2022, of the period to regain compliance with its minimum bid price per share requirement. "Operating as a publicly-traded company on Nasdaq provides us with several advantages, including greater access to capital to fund our pipeline, improved liquidity for our shareholders and a higher likelihood of attracting high-quality institutional investors and commercial partners," stated Dr. Joseph Sarret, Chief Executive Officer. "It is imperative that we maintain our listing and we are pleased that Nasdaq has provided us with an extension. We strongly recommend that our shareholders vote in favor of the reverse split proposal ahead of our Annual Meeting to maintain our listing and help us build long-term value."

09:07 EDT Stratasys says MakerBot to merge with Ultimaker - Stratasys announced that its subsidiary MakerBot has entered into a definitive business combination agreement with NPM Capital-backed Ultimaker to form a new entity. The new combined company is intended to offer a comprehensive solution set of hardware, software and materials, creating a leading force in Desktop 3D printing. Under the terms of the agreement, NPM Capital plans to contribute Ultimaker's assets, invest $15.4 million, and own 54.4% of the combined company, while Stratasys will contribute MakerBot's assets, invest $47 million, and own 45.6% of the combined company. The combined $62.4 million of committed financial backing is intended to fuel ecosystem innovation and expand customer reach and applications. The new company will be led by Nadav Goshen, current MakerBot CEO, and Jurgen von Hollen, current Ultimaker CEO, who will act as Co-CEOs, with Nadav managing product, operations and R&D and Jurgen managing the commercial functions. The entity is expected to maintain its headquarters in both The Netherlands and New York City. Upon closing, the transaction is not expected to have a material impact on Stratasys' revenue and is expected to be immediately accretive. As Stratasys will own less than 50% of the new entity, Stratasys will not consolidate it. The transaction is subject to consultation with appropriate employee representative bodies and the receipt of regulatory approvals, and satisfaction of other customary closing conditions, as a result of which a definitive time frame for closing is not yet available, with closing currently expected over the course of the second or third quarters of 2022.

09:06 EDT Advantage Solutions acquires Brandshare - Advantage Solutions has acquired Brandshare from private equity investors Aperion Management, Leeds Novamark Capital and Ocean Avenue Capital Partners. "We're committed to continually investing in new ways to deliver transformative omnichannel sales and marketing services that help brands and retailers get products into the hands of consumers wherever they are and however they shop," said Advantage Solutions CEO Jill Griffin. "Brandshare's expertise and capabilities highly complement Advantage's own, including our industry-leading in-store sampling services and our suite of sampling innovations, such as online grocery pickup and delivery sampling and digital product demonstrations, which we quickly scaled up during the pandemic to help our clients connect with shoppers in new ways.

09:06 EDT PepsiCo taps Billtrust's ACA solution for hard Mountain Dew distribution - Billtrust (BTRS), a B2B accounts receivable automation and integrated payments leader, announced that PepsiCo (PEP) has successfully deployed its automated Credit Application solution to support the distribution of HARD MTN DEW, a new Mountain Dew-branded alcoholic beverage. For the distribution, Blue Cloud Distribution a wholly owned subsidiary of PepsiCo, needed to quickly configure a credit solution, where legal, to onboard hundreds of new distributor partners and meet the increased credit demand while complying with varying state requirements. By implementing Billtrust's Credit Application solution, BCD is now maximizing customer satisfaction, eliminating paper use and achieving 99% of credit application approvals within a day of submission. BCD uses Billtrust's Credit Application to support other business units. "We already process between seven and ten thousand new customers each year with Billtrust Credit Application, but entering a new business offered our team a new set of challenges," said Mike Bevilacqua, Senior Director, Credit & Collections, PepsiCo. "We worked hand-in-hand with the Billtrust team to address the complexities of multiple state requirements, each with different terms, and were able to quickly stand up a whole new division within a short timeline."

09:05 EDT Euronet's Ria Money Transfer announce partnership with Rebtel - Ria Money Transfer, a business segment of Euronet Worldwide, announced a new partnership with Rebtel, an international calling service provider based in Sweden. The partnership embeds Ria's international money transfer service directly into Rebtel's digital platform. Ria offers payments to bank accounts, mobile wallets, and cash across 170 countries and territories and is powered by Euronet's Dandelion service. "Behind every money transfer there is a story, and it usually starts with someone calling home, caring for family, or making a loved one's life better," said Juan Bianchi, CEO of Euronet's Money Transfer Segment. "We've spent over 35 years building an inclusive, real-time payments network that empowers people to send money home, including those people championed by Rebtel. This partnership is a great example of the affinity of our brands with services that are fast, easy, safe and have no hidden fees."

09:04 EDT Chevron releases new Delo jug - Chevron Products Company announced the release of a new package design for its full line of Chevron Delo heavy duty diesel engine oils - including the new Delo 400 XSP SAE 15W-40 full synthetic, high-performance engine oil for diesel pick-up trucks. The 1-gallon jug will feature a two-handle system for improved handling and a smoother "no-glug" pour. Both the 1- and 2.5-gallon jugs include new label designs for easier product selection and will feature a QR code for immediate access to comprehensive product details. The transition to the new packaging will take place beginning this month.

09:04 EDT AstraZeneca joins Accumulus Synergy as sponsor - Accumulus Synergy announced AstraZeneca has joined Accumulus Synergy as a sponsor company. "Accumulus Synergy has embarked on an ambitious goal and a critical mission to transform the procedures that underpin the regulatory submission process - and this is strongly aligned with AstraZeneca's goal to accelerate the discovery, development and delivery of innovative medicines for patients. We are excited to collaborate with Accumulus Synergy to improve efficiencies and pioneer new processes for facilitating the review of critical medicines," said Jacques Mascaro, Ph.D., MBA, Senior Vice President, Oncology Regulatory Science, Strategy and Excellence, AstraZeneca, who has also been appointed as a Board Member of Accumulus Synergy.

09:03 EDT SunPower partners with Ikea U.S. for home solar solutions - SunPower and IKEA U.S. are teaming up to make solar energy easier to access. Through this collaboration, members of the IKEA Family customer loyalty program will be able to purchase home solar solutions, available through SunPower, to generate and store their own renewable energy. Home Solar with IKEA is expected to launch in select California markets in Fall 2022.

09:02 EDT D-Orbit successfully completes fifth ION satellite carrier mission - D-Orbit, the space logistics and orbital transportation company in the process of going public through a transaction with Breeze Holdings Acquisition, announced the successful completion of the Company's fifth mission, Spacelust. The deployment phase of the mission ended after D-Orbit's versatile and cost-effective orbital transfer vehicle, OTV, ION Satellite Carrier, ION, successfully deployed a pair of small customer satellites from Kleos Space. In addition, over the weeks preceding the final deployment operation, ION fired Dawn Aerospace's B20 thrusters and successfully performed a change in the orbit inclination and RAAN parameters to release KSF2a and KSF2b, the last two of the four Kleos' Patrol Mission satellites onboard. "Another mission completed and another terrific job by our team at D-Orbit," said Renato Panesi, Ph.D., D-Orbit's Chief Commercial Officer. "We are proud to have served our customers on Spacelust. With each mission we complete, we are demonstrating the strength of our technology and our steady progression along our roadmap."

08:56 EDT Newegg Commerce shares insights about Newegg Live - Newegg shared insights about its live video commerce platform, Newegg Live. Launched in September 2021 and produced by the company's media team for the Newegg mobile app and TikTok, Newegg Live is an interactive, real-time livestream showing some of the most in-demand tech products available on the Newegg platform. Airing several episodes per week, Newegg Live demonstrates products at exclusive sale prices typically available only for the duration of the livestream. Show hosts also produce and write their own scripts. Programming emphasizes interaction between the brand and its customers, who type questions or comments in the chat for the hosts to offer a response. Viewers can ask questions about the products to make more informed buying choices. The tech solution enables viewers to make purchases directly in the Newegg mobile app or on TikTok while watching the video. The video is also available to watch later on social media platforms. Newegg Live engages with current and new customers in a way that is more entertaining than typical e-commerce shopping. Hosts offer a three-dimensional perspective of products, in-depth descriptions and the ability to show features of products like their capabilities, sounds and video. Show hosts also produce and write their own scripts. Answering questions through host conversations or demonstrating product features are crucial to keep audiences engaged. The show has also been integral in expanding the product categories associated with the Newegg brand. While the company features some of its top-tier brands and products like gaming PCs, computer components, monitors and other products in core categories, the livestream has also created opportunities for new sellers to feature products on episodes.

08:49 EDT American Manganese reschedules shareholder meeting - American Manganese has rescheduled its annual general and special meeting of shareholders to July 8, 2022, at 11:00 a.m. Further details on the meeting will be contained in a new Notice of Meeting and the management information circular that will be mailed to shareholders and filed on SEDAR.

08:47 EDT Everbridge: India's Maharashtra selected company's Incident Response Solutions - Everbridge announced that the Indian State of Maharashtra selected the company's Incident Response Solutions to help governments plan for, respond to, and recover from any disaster. Home to a combined 150 million residents and annual tourists, Maharashtra is the second-most populous state in India, and its capital Mumbai is the most populous city in the country.

08:45 EDT Vallon Pharmaceuticals reports additional data from SEAL study of ADAIR - Vallon Pharmaceuticals reported additional results from the SEAL study evaluating the abuse potential of ADAIR. ADAIR is the Company's proprietary abuse-deterrent formulation of immediate-release dextroamphetamine currently in development for the treatment of attention deficit hyperactivity disorder, ADHD, and narcolepsy. In March 2022, the Company reported topline results from its SEAL study. The SEAL study was the Company's pivotal intranasal human abuse liability study assessing the pharmacodynamics, pharmacokinetics, safety and tolerability of snorting professional laboratory-manipulated ADAIR 30 mg when compared to crushed d-amphetamine sulfate and placebo in recreational drug users. Summary of Additional Data from the SEAL Study Vallon has completed its initial analysis of the full data set and has received final tables, figures, and listings for the study. Pharmacokinetic analysis showed that professionally manipulated ADAIR taken intranasally demonstrated a blunted pharmacokinetic profile compared to crushed and snorted dextroamphetamine including lower maximum blood levels of dextroamphetamine, a longer time to maximum blood concentrations, and lower overall drug exposure especially during the early time points up to 1, 2, and 4 hours after dosing. As previously reported, secondary endpoints of Overall Drug Liking and willingness to Take Drug Again at 12 and 24 hours post-dosing were all statistically significantly lower for manipulated ADAIR taken intranasally compared to crushed and snorted reference dextroamphetamine. On the additional endpoints of Emax Overall Drug Liking and Emax Take Drug Again, ADAIR was also statistically significantly lower than reference dextroamphetamine. As previously reported, ADAIR intranasal demonstrated higher scores on each of the 5 components on the Subject Rated Assessment of Intranasal Irritability suggesting that manipulated ADAIR was more irritating and less comfortable to snort than crushed dextroamphetamine. The additional analysis confirms that all of those differences were statistically significant. On the pharmacodynamic endpoint of "Feeling High" ADAIR IN was significantly lower than reference Dextroamphetamine IN. On the endpoint of "Good Effects," there was a strong trend towards lower scores with ADAIR IN; there were no significant differences on the endpoint of "Bad Effects." The overall safety and tolerability profile of ADAIR in the SEAL study was consistent with the well-established profile of dextroamphetamine. ADAIR was generally well tolerated, and the safety profile of all active treatment arms was consistent with the known effects of amphetamine, with no unexpected adverse events reported. "While we were disappointed we did not meet our primary endpoint for the SEAL study, we are encouraged by the additional results found upon further analysis of the data which show favorable outcomes on additional secondary and exploratory pharmacokinetic and pharmacodynamic endpoints," commented David Baker, President & CEO of Vallon. "We are continuing to work with our advisors and partners to assess the full data set from the SEAL study and to evaluate next steps and a potential path forward for the ADAIR development program."

08:44 EDT Idaho Strategic announces addition of Lemhi Pass REE project in Idaho - Idaho Strategic Resources is pleased to announce its newly added Lemhi Pass Rare Earth Element project and claim group in the Lemhi Pass area of central Idaho. IDR's newest addition is a strategic land package consisting of 25 unpatented claims, covering an area of approximately 425 acres in the northeastern part of the Lemhi Pass District. The northeastern portion of Lemhi Pass contains the greatest concentration of veins where the large Lemhi Pass, Bull Moose, and Dan Patch faults either intersect or approach one another. Although prior REE assay values within this area are very limited, this newest addition is a high-quality claim block covering most of the area's historical highest recorded REE values. Lemhi Pass is officially recognized as one of the most important critical mineral districts in the United States. It hosts a wide variety of critical minerals from technology metals, such as rare earths and niobium, to energy generating metals like thorium. The Company believes that while Idaho's REE-Th Belt is not yet as popular as the well-known Idaho Cobalt Belt, it has the potential to be an important source of the technology and energy metals required to support our nation's decarbonization goals and domestic supply chain security. Given the increased activity in the Lemhi Pass District over the past year, IDR has benefitted tremendously from its first-mover advantage, proven 'producer' status and the relationships it has developed with fellow Idaho stakeholders in the area. The Lemhi Pass District is in the southeastern part of the 70-mile-long by 10-mile-wide northwest trending belt known for containing Rare Earth Elements and Thorium in abundance. The Idaho REE-Th Belt possesses most of the known REE lode occurrences in Idaho and extends from the Lemhi Pass District in the southeast through the Mineral Hill District. Within this 70-mile belt lies IDR's Roberts Property in the northwest, Diamond Creek Property in the middle, and our new Lemhi Pass Property in the southeast. The Lemhi Pass area was historically prospected for copper and gold until the sudden demand for uranium arose in the late 1940's following World War 2. This demand fueled U.S. government sponsored nationwide exploration for nuclear power related raw materials, which resulted in the discovery of thorium at Lemhi Pass in 1949. The commercial potential of these REE and thorium deposits was recognized by the 1950's; but the subsequent Cold War yet again shifted our nation's focus to uranium for its weaponization potential, minimizing the exploration work sponsored by the Dept. of Energy, Atomic Energy Commission and others. Thus, strategic interest in Idaho's REE-Th Belt faded until the implementation of two Executive Orders addressing REE's, and most recently by the Biden administration enacting the Defense Production Act to increase domestic mining and processing of critical materials for the large capacity battery supply chain and related technologies.

08:42 EDT CorMedix announces leadership updates, operational changes - CorMedix (CRMD) announced updates regarding its leadership team and changes regarding its international operations: Joe Todisco, Chief Executive Officer of CorMedix, officially joined the organization on Tuesday May 10th. Liz Hurlburt, EVP of Clinical Operations, has been promoted to an expanded role as EVP of Clinical & Medical Affairs, assuming oversight of Medical Affairs, Drug Safety and Pharmacovigilance, in addition to her existing Clinical Operations responsibilities. Donna Ucci has joined the Company as Senior Vice President and Head of Global Quality, reporting directly to the CEO. Donna joins CorMedix after most recently serving as VP Global Quality Management at Amneal Pharmaceuticals (AMRX). Frank Raffaele has joined the company as VP of Supply Chain, and brings more than 30 years of manufacturing and supply chain experience, most recently with Quotient Sciences. The Company and Tom Nusbickel, EVP and Chief Commercial Officer, have mutually agreed to part ways. The Company will begin the process of winding down its European operations and will discontinue the distribution of Neutrolin, which is CE marked as a medical device in Europe. The Company intends to focus near-term efforts on securing NDA approval and commercialization of DefenCath in the US market.

08:38 EDT Revitalist Lifestyle and Wellness reports April revenue C$480,000 - REVITALIST LIFESTYLE AND WELLNESS is pleased to report updates on strategic initiatives accomplished in April including becoming a founding partner with the American Association of Psychedelics. Revenue - April 2022 sales of approximately $480,000 CAD represented a 319% increase from the same month in 2021 and a 15% increase compared to March 2022. Insurance - Over 80 medical and mental health providers directly associated with Revitalist have now been accepted and considered to be "in-network" with top commercial insurance payers including Blue Cross Blue Shield, Aetna, Cigna, Humana, Optum, United Healthcare, and federal insurers including Veterans Affairs Community Care Network and Medicare. "In network" verifies the providers have met the insurers quality standards giving greater financial security to consumers and payers. Research - Revitalist receives acceptance to present at the American Psychiatric Nursing Association's National Conference discussing its findings on Case Report: Adult with Bipolar Disorder and Autism treated with Ketamine. To request a copy of this report, please email us at corporate@Revitalist.com Education - Revitalist becomes founding partner with the American Association of Psychedelics. The inaugural conference, "Ethics Safety, Science" takes place in Knoxville, TN, November 17-20, 2022. To learn more visit AAPsychedelics.org Metaverse - Revitalist's partnership with Metachain Technologies Inc. to create virtual mental health and wellness clinic chains through its subsidiary, Revitaland, enters alpha testing phases. Revitalist CEO, Kathryn Walker, states: "April was a terrific month for the Company. We closed the first tranche of our financing for $3,869,000 and ended the month with our best sales performance yet. Considering the barriers many companies are facing at this time with inflation and market fluctuations, this proves the strength of our company even in trying times. I am continuously amazed as we continue to trail blaze this industry executing at accelerated speeds in various revenue producing capacities changing and saving lives every day."

08:36 EDT Jaguar Mining expects to deliver towards lower end of production guidance - The Company expects to deliver towards the lower end of its annual production guidance of 86,000 to 94,000 ounces. At the lower end of the guidance, with a US$ to Brazilian Real foreign exchange ranging between R$5-5.30 and incorporating the impacts of the cost savings initiative, the Company expects to meet the higher end of the annual cost guidance of $1,150 to $1,250 per ounce for the remaining part of the year 2022.

08:35 EDT Tapestry expects 35% revenue decline in China in Q4 - Cites ongoing Covid-19 restrictions.

08:33 EDT State Street launches SPDR MarketAxess Investment Grade 400 Corporate Bond ETF - State Street Global Advisors, the asset management business of State Street Corporation announced the launch of the SPDR MarketAxess Investment Grade 400 Corporate Bond ETF. Designed to blend the advantages of an ETF with the tradability benefits of investing in US Investment grade corporate bonds with higher liquidity compared to the broader U.S. corporate bond market, LQIG offers investors credit exposure with the potential for tighter bid-ask spreads, lower premium/discounts, and more transparency into the underlying holdings' real-time valuations.

08:32 EDT Desktop Metal launches DuraChain photopolymers - Desktop Metal announced DuraChain - a first-of-its-kind commercial category of photopolymers that uses a material chemistry process known as Photo Polymerization-induced Phase Separation, or Photo PIPS, to deliver breakthrough material properties. Parts produced with standard acrylate-based resins used in DLP 3D printing today are prone to shattering or fracturing upon impact. For decades, the 3D printing industry has been working to incrementally improve these material properties and deliver more durable and elastomeric properties.

08:27 EDT Tapestry says drove 'outsized' revenue growth in the digital channel in Q3 - Says e-commerce represented about 30% of sales in Q3. Says Coach average prices have increased for 12 straight quarters. Expects "exceptional margins" for Coach in FY22. Expects Coach to reach $5B in revenue in FY22. Sees Stuart Weitzman brand returning to profitability in FY22. Says "company foundation is solid, brands poised for growth." Says trends in China weakened through the quarter due to Covid-19 restrictions. Comments taken from Q3 earnings conference call.

08:26 EDT Priority Technology to launch solution for construction payment challenges - Priority Technology Holdings will be launching their next vision for solving the construction payment challenges at the Construction Financial Management Association annual conference scheduled for May 14-18, 2022 in Atlanta. Representatives from Priority will be available throughout the conference to engage with attendees, answer questions, highlight products, and participate in the broader conversation happening among thought leaders at the forefront of construction finance. Cash flow management will be a frequent topic of discussion considering a recent survey showing that 84% of construction firms experienced cash flow issues in the preceding 12 months, and nearly 20% dealt with them on a constant basis. Another survey showed that cash flow problems reduce profits for 47% of firms, delay projects for 33%, and lead 30% to take out loans. More than just an annoyance, cash flow problems create chaos and cut deep into the bottom line in ways that it's hard (or impossible) to recover from. Seeing a golden opportunity to both add to and learn from this discussion, Priority relishes the chance to engage with anyone and everyone at the CFMA conference. The issues relevant to construction finance professionals are the same ones that Priority strives to solve with an all-encompassing platform that integrates payment and banking infrastructure into a single solution driven by automation. By combining together the constituent parts of construction finance, streamlining how money moves in and out of accounts, and automating time, labor, and error-intensive workloads, Priority transforms how construction handles payments.

08:25 EDT Biomerica announces CE Mark for H. pylori diagnostic test, hp+detect - Biomerica announces CE Mark for its hp+detect diagnostic test that detects Helicobacter pylori bacteria. The company will begin to market and sell its hp+detect diagnostic test in the European Union and other international countries following registration of the product in each country in which it is sold.

08:23 EDT Bowman Consulting appoints Ray Vicks to board of directors - Bowman Consulting Group announced it increased the size of its board of directors and appointed Ray Vicks as an independent director, effective May 11, 2022. Vicks spent more than 33 years in public accounting, including sixteen years as a partner at PricewaterhouseCoopers, where he focused on the external audit and advisory risk management practice areas. The board accepted the resignation of Dan Lefaivre as a director effective immediately after the filing of the Company's 10-Q. Mr. Vicks will assume the role of Chair of the board's audit committee and will become a member of the board's nominating and governance committee.

08:23 EDT Huntington Bancshares acquires fintech Torana - Huntington Bancshares subsidiary Huntington National Bank has acquired Digital Payments Torana, a business-to-consumer payments fintech based in San Francisco. Torana's payment solution is a software as a service model built in the cloud and will enable Huntington and its clients to distribute digital payments to a variety of end users. Terms of the transaction were not disclosed.

08:21 EDT First American appoints Marsha Spence to board of directors - First American Financial Corporation announced that Marsha Spence has been appointed to the company's board of directors. Over the course of her distinguished 45-year career in title and settlement, Spence's skillful leadership has consistently produced high-performing teams and profitable growth at Mother Lode Holding Company, a California-based provider of title insurance, underwriting and escrow services for residential and commercial real estate transactions known for its strong employee-centric culture

08:21 EDT Enphase Energy expands battery storage in Missouri - Enphase Energy announced that installers of Enphase products in Missouri have seen growing deployments of Enphase Energy Systems powered by IQ Microinverters and IQ Batteries, as severe weather such as winter ice storms, tornadoes, and summer flooding continues to impact homeowners in the Midwest. "We take pride in supporting an excellent customer experience and giving homeowners more peace of mind about their energy future," said Dave Ranhoff, chief commercial officer at Enphase Energy. "We're proud to partner with installers across Missouri to help homeowners invest in an all-in-one home energy solution from Enphase and meet their desired energy needs."

08:20 EDT NanoXplore, Molding Products execute long-term supply agreement - NanoXplore announced that it has entered into a long-term supply agreement with Molding Products LLC to produce and sell graphene-enhanced Sheet Molding Compound called GrapheneBlack SMC, used to create high quality, lightweight composite exterior and battery enclosure parts for cars and trucks, such as hoods, bumpers, roofs, and battery packs.

08:20 EDT NRx Pharmaceuticals begins enrollment in Phase 2 bipolar depression study - NRx Pharmaceuticals announced that the first patient has been enrolled in one of the two psychiatry studies that it plans to initiate this year: this first trial is studying patients with bipolar depression and sub-acute suicidality - not requiring hospitalization -. In the second half of this year, NRx Pharmaceuticals expects to initiate a Phase IIb/III registrational trial in patients with bipolar depression and acute suicidal ideation and behavior, which requires hospitalization of the patient. The FDA previously awarded Breakthrough Therapy Designation for NRX-101 for this last indication, based on positive Phase II data that the company submitted. NRX-101 is an oral, patented, fixed-dose combination product of D-cycloserine and lurasidone. Both components are approved drugs that are not scheduled, as available data has not shown potential for abuse.

08:19 EDT Bragg's Wild Streak strengthens game development collaboration with IGT - Wild Streak Gaming , a Bragg Gaming Group company (BRAG), has expanded its collaboration with International Game Technology (IGT) with an agreement to develop four exclusive land-based slot titles for the leading gaming technology supplier. The agreement is an extension of a successful relationship between the two parties, with the most recent extension for four titles occurring in August of 2021. Wild Streak has produced multiple strong slot titles for IGT including Wolf Run Gold along with the latest solid performers Queenie and Dreamy Genie. The next Wild Streak developed title to be released by IGT in Q2 2022 is Greek/Lucky Lightning, a unique game with two variations depending on how many credits are played on each spin. Las Vegas-based content creation studio Wild Streak Gaming was acquired by Bragg Gaming Group in June last year and offers a popular portfolio of casino games that are offered by land-based, online and social casino operators in global markets including in North America and Europe. Doug Fallon, Managing Director of Group Content at Bragg Gaming Group and Founder of Wild Streak, said: "We have enjoyed a productive and long-standing collaboration with IGT and are delighted to expand our relationship with them for the development of an additional four titles for their land-based slot operations."

08:19 EDT Protara Therapeutics presents results of retrospective analysis of OK-432 - Protara Therapeutics announced the results of a retrospective analysis of OK-432, the originator compound for TARA-002, Protara's investigational therapy in development for the treatment of lymphatic malformations, LMs. LMs are serious, rare, congenital malformations of lymphatic vessels. The results from the analysis, which were presented during a poster presentation at the International Society for the Study of Vascular Anomalies, ISSVA, World Congress 2022, showed that OK-432 was clinically successful and generally well-tolerated in the treatment of both macrocystic and mixed-cystic LMs. The retrospective analysis included 246 patients from a Phase 2 randomized study, and 275 patients from an open-label study. In the first study, patients were randomized 2:1 to receive treatment immediately or delayed by six months. In the open-label study, patients received four doses of OK-432 approximately six weeks apart. The primary efficacy endpoint was clinical success in the ITG versus spontaneous resolution of the LM in the DTG. Efficacy was assessed two weeks post-treatment in the randomized study, and one to six months post-treatment in the open-label study. Key findings are summarized below: Approximately 69% of patients in the randomized study ITG achieved clinical success after six months, while only 7.5% of patients in the DTG showed spontaneous resolution of LMs in the same time period. 73.1% of patients in the open-label study achieved clinical success. In the randomized and open-label studies, 10 of 219 and 5 of 275 subjects, respectively, were reported to have treatment emergent serious adverse events that were assessed by the investigator as related to study drug. The most severe adverse events were airway obstruction and facial paralysis due to swelling post-injection that required tracheostomy and hospitalization. Local/systemic reactions peaked in the first few days and resolved within two weeks. Patients were followed for up to three years post treatment with no significant safety concerns.

08:18 EDT Dine Brands increases quarterly dividend 11% to 51c per share - Dine Brands Global announced that its Board of Directors declared and approved an 11% increase in the quarterly cash dividend to $0.51 per share of common stock. The dividend will be payable on July 8, 2022, to the Company's stockholders of record at the close of business on June 20, 2022.

08:17 EDT Morphic names Bruce Rogers as president, Blaise Lippa as CSO - Morphic Therapeutic announced two key executive appointments. Dr. Bruce Rogers has been named President of Morphic Therapeutic and Dr. Blaise Lippa, has been named Chief Scientific Officer. Dr. Rogers previously served as Morphic's Chief Scientific Officer and Dr. Lippa served as Morphic's Senior Vice President and Head of Molecular Discovery.

08:16 EDT red violet's FOREWARN partners with BCSRMLS - FOREWARN, a red violet company, announced that Bryan College Station Regional MLS, BCSRMLS, has contracted to make FOREWARN services available for the 1,500+ REALTOR members it serves across Brazos, Burleson, Grimes, Leon, Madison, & Robertson Counties to promote proactive real estate agent safety. "We are very pleased to be providing this essential tool for the safety of our members," said Janna Burton, CEO of Bryan College Station Regional MLS. "Having the power of FOREWARN at their fingertips is a game changer for agents. It gives them the ability to verify the identity and potential risks associated with a prospect in seconds. It really is amazing, and we are thrilled to be helping our members to protect themselves well in advance of meeting with unknown prospects."

08:15 EDT Rockwell Medical submits additional home infusion IND application data to FDA - Rockwell Medical provided the FDA with the supplemental data, requested by the agency in December 2021, for the company's pending Investigational New Drug application in support of a proposed Phase 2 clinical trial of Ferric Pyrophosphate Citrate - FPC - for the treatment of iron deficiency anemia and maintenance of hemoglobin in patients receiving infusion therapy in the home setting. The additional data relate to the physical, chemical and microbiological stability of FPC in support of the suggested method of administration in the Phase 2 protocol. The FDA has 30 days to review the additional data that have been submitted. In the event that the FDA has no further questions or requirements regarding the submission, the company would expect the trial to start shortly after the review period ends.

08:14 EDT Sprinklr enters partnership with Twilio for contact center - Sprinklr announced a new partnership with Twilio. By integrating Twilio voice and SMS technology with Sprinklr Modern Care, Sprinklr customers can now create the next generation of contact center - a comprehensive, cloud-based platform for true omnichannel customer care. Modern enterprises understand the need to unify contact center, customer care, and customer experience functions. Twilio provides best-in-class communications platform as a service infrastructure, while Sprinklr Modern Care delivers an out-of-the-box, AI-powered contact center as a service application layer built on the world's only Unified-CXM platform.

08:13 EDT Agilysys names Terrie O'Hanlon as CMO - Agilysys announced that it has hired Terrie O'Hanlon as its chief marketing officer CMO . In this newly created role, O'Hanlon will focus on amplifying the technology leader's global market presence and driving revenue growth through global marketing initiatives.

08:11 EDT Tapestry sees FY22 gross margin down vs. prior year - FY22 gross margin inclusive of 260 bps of headwinds from higher freight costs. Sees FY22 operating margin decline of over 70 bps vs. prior year. Sees FY22 tax rate about 18%. Comments taken from investor presentation slides for Q3.

08:08 EDT Monopar Therapeutics plans to raise additional funds within next 12 months - Cash and cash equivalents as of March 31, 2022 were $17.8M. Monopar anticipates that its current cash and cash equivalents will fund: the Phase 2b portion of the VOICE clinical trial; the commencement of the Phase 3 portion of the VOICE clinical trial; and the Phase 1b camsirubicin clinical trial through at least June 2023. The company plans to raise additional funds and/or engage a partner within the next 12 months to complete the VOICE clinical program and continue camsirubicin clinical development through and beyond the ongoing open-label, dose escalation Phase 1b clinical trial.

08:07 EDT Indaptus Therapeutics reports submission of IND for Decoy20 - Indaptus announces the submission of its Investigational New Drug Application for Decoy20. The company continues to expect to initiate a Phase 1 clinical trial for Decoy20 targeting solid tumors in 2022. Importantly, the company has successfully completed GMP manufacturing and IND-enabling multi-dose toxicology studies that have not produced sustained induction of factors associated with cytokine release syndromes. Earlier pre-clinical data have demonstrated Decoy20's ability to eradicate established tumors in a murine model of hepatocellular carcinoma in combination with either a non-steroidal anti-inflammatory drug or an anti-PD-1 agent, and more efficiently with both. In combination with low-dose chemotherapy, Decoy candidates have also produced highly efficient eradication of established tumors in a mouse model of non-Hodgkin's lymphoma, also with induction of immunological memory.

08:05 EDT Lipocine's LPCN 1144 shows positive safety results in NASH extension study - Lipocine announced positive topline results from its Open Label Extension study, OLE. LPCN 1144 comprises an orally delivered prodrug of testosterone. Twenty-five subjects were enrolled, twenty-three completed the study. LPCN 1144 was well tolerated over 72-week exposure with no observed safety signals. There were no reported cases of cardiovascular events, thromboembolic events, hepatocellular carcinoma, or drug induced liver injury. Weight change from baseline was minimal and comparable to the LiFT results. Liver injury markers were reduced significantly and maintained with extended LPCN 1144 treatment. Further, subjects exposed to 72-weeks of LPCN 1144 treatment maintained the mean liver injury marker reductions. Observed improvements in liver histology support further development. Utilizing NASH CRN scoring, in the limited number of biopsies LPCN 1144 treatment showed improved efficacy upon extended treatment, and treatment post 36-week placebo run-in demonstrated efficacy consistent with the LiFT study results.

08:03 EDT Mahmee raises $9.2M Series A led by Goldman Sachs Asset Management - Mahmee announced the closing of a $9.2 million Series A round led by the Growth Equity Business within Goldman Sachs Asset Management. The round also features participation from existing investors including Revolution's Rise of the Rest Seed Fund, Muse Capital, Backstage Capital, The Helm, and Pipeline Angels. As part of the round, Anna Mason, Managing Partner at Revolution's Rise of the Rest Seed Fund, will join Mahmee's board of directors. New investors include Episcopal Health Foundation of Texas, Third Culture Capital, Black Pearl Investment Group, She Raises Capital, and Lawrence Platt, MD, pioneering board certified obstetrician-gynecologist and maternal-fetal medicine specialist and member of Mahmee's clinical advisory committee.

08:02 EDT Asahi Kasei to start providing carbon footprint data for rubber, elastomers - Asahi Kasei has developed a system to calculate the carbon footprint of products for the synthetic rubber and elastomers products Asadene, Tufdene, Asaprene, Tufprene, Asaflex, Tuftec, and S.O.E with CFP data provision to customers scheduled to begin in June 2022. CFP visualization is achieved utilizing the DEEP3 group-wide management infrastructure as a part of the System, which also enables examination of ways to further reduce CFP. The Asahi Kasei Group made efforts to strengthen the business platform for sustainable growth from the viewpoint of Green, Digital, and People in its previous medium-term management plan, Cs+ for Tomorrow 2021. In its new medium-term management plan, announced on April 11, 2022, Green Transformation is positioned as one of the key areas for strengthening the management foundation, and Asahi Kasei is advancing reductions of its own GHG emissions as well as contributions to reducing the world's GHG emissions for the realization of carbon neutrality. Therefore, from the perspective of GHG emissions reduction, Asahi Kasei has sequentially advanced the calculation of CFP for each product starting with the main products, and information provision to certain customers has begun. As part of the effort to accelerate Green Transformation, Asahi Kasei has begun procuring butadiene derived from plastic waste and biomass as feedstock for solution-polymerized styrene-butadiene rubber, a material for eco-friendly tires4.

08:02 EDT Pacira reports preliminary April net product sales for Exparel, iovera of $45.8M - Pacira BioSciences reported preliminary unaudited net product sales for EXPAREL and iovera for the month of April 2022. EXPAREL net product sales were $44.8 million, compared with $43.1 million for April 2021. EXPAREL average daily sales for the month of April 2022 were 109 percent of April 2021. The company reports average daily growth rates for EXPAREL to account for differences in the number of selling days per reporting period. The number of EXPAREL selling days were 21 in April 2022 and 22 in April 2021. Net product sales of iovera degrees were $1.1 million for the month of April 2022, compared with $1.5 million for April 2021. "We are pleased to report solid EXPAREL growth as we support the market transition to outpatient sites of care, with utilization expanding and significantly outperforming the elective surgery market amidst pockets of persistent operating disruptions and healthcare labor shortages," said Dave Stack, chairman and chief executive officer of Pacira BioSciences. "ZILRETTA and iovera degrees are gaining traction and we expect improving sales trends for both products as the year progresses and we build awareness around their value as both complementary and standalone non-opioid solutions for managing osteoarthritis. Importantly, we continue to execute from a position of financial strength having recently reported adjusted EBITDA of $53.8 million in the first quarter of 2022 and having ended the first quarter with a significant cash position. As such, we remain highly confident in our outlook for robust revenue and earnings growth as we cement our leadership position and deliver patients innovative, non-opioid solutions along the neural pain pathway."

07:50 EDT Ameresco in supply pact with Powin for 2,500 MWh of BESS - Ameresco announced that they have signed a long term non-exclusive purchasing framework agreement for Powin to supply Ameresco with 2,500 MWh of its modular BESS Stack750 product as part of its Centipede hardware platform. The long-term purchase agreement is intended to supply a portion of Ameresco's BESS needs through mid-2025 and be utilized in Ameresco's project and asset installations for a wide array of customers ranging from small municipal utilities to large Federal projects. Ameresco chose Powin's system because the modular design of the Stack750 product is well suited for a variety of Ameresco's customer needs and requires decreased lead time to deploy, reduced space on-site, and a lower overall capital cost. "Building on our experience with BESS projects across the globe, we are excited to agree to this supply to help meet our growing demand for battery energy storage technologies as a part of our comprehensive customer solution set," said Doran Hole, EVP and Chief Financial Officer, Ameresco. "As costs have declined and the technology matured, battery storage has rapidly become a go to clean energy technology. Whether as a standalone system or as part of an integrated solar or microgrid solution, BESS have become an integral technology for customers looking to increase energy resiliency and reliability. This agreement is designed to bolster our BESS availability with a high quality, flexible product and offer advantageous equipment delivery timelines to support our growing base of customers throughout our various vertical markets."

07:49 EDT WestRock publishes 2021 sustainability report - WestRock announced the publication of WestRock's 2021 Sustainability Report, detailing the comprehensive efforts the company is making for, and with, customers to imagine and deliver on the promise of a sustainable future. The report reveals validation of WestRock's greenhouse gas emissions reduction target by the Science Based Targets Initiative alongside its refreshed sustainability goals. The report advances WestRock's sustainability strategy, emphasizing the key environmental, social and governance components of its core pillars: Supporting People and Communities: Serving the people we rely on and those who rely on us. Striving for a 100% safe culture by driving continuous improvement to reduce risk in the workplace and by supporting our teammates' well-being; Investing in programs and systems to advance our leadership in diversity, inclusion and belonging for our teammates, customers, industry and communities. Bettering the Planet: Championing sustainable forestry and protecting the environment. A science-based target to reduce: Absolute Scope 1 and Scope 2 GHG emissions by 27.5% by 2030 from a 2019 base year; Absolute Scope 3 GHG emissions from purchased goods and services, fuel and energy activities, upstream and downstream transportation and distribution, and end of life treatment of sold products by 27.5% by 2030 from a 2019 base year. Promoting sustainable forestry and seeking to ensure forests where we operate remain forest positive by: Sourcing 100% of virgin fiber from responsibly managed forests; Investing in the future of sustainable forestry by supporting certification of 1.5 million acres of forestland to recognized forest management standards by FY30; Innovating for Our Customers and Their Customers: Innovating to achieve a more circular economy. By 2025, 100% of WestRock's products will be recyclable, compostable or reusable, driving the transition to a more circular economy through cutting edge innovation

07:47 EDT Carbon Streaming announces first biochar carbon stream - Carbon Streaming Corporation is pleased to announce that it has entered into a carbon credit streaming agreement with a subsidiary of Restoration Bioproducts to support construction of a biochar production facility in Virginia. Biochar, short for biological charcoal, is produced by heating organic feedstocks in a limited oxygen atmosphere, resulting in a very stable form of carbon that prevents the release of greenhouse gases into the atmosphere for centuries, making it valuable for sequestration purposes. CO2 Removal Certificates are expected to be verified under independent standard Puro.earth, the leading standard for Biochar projects. Investment Highlights: This is the Company's first carbon stream on a biochar carbon removals project, providing diversification across a new project type. This is the Company's first carbon stream located in the United States, furthering geographic diversification. Carbon Streaming will receive and sell 100% of the CORCs generated by the Project, with ongoing payments to Restoration Bioproducts for each CORC sold under the Stream Agreement. The Project is expected to remove over 161,000 tonnes of CO2 equivalent emissions over the 25-year project life and generate an equivalent number of CORCs. CORCs from other Puro.earth projects are currently selling above US$125/CORC as of April 2022. With the signing of the Stream Agreement, Carbon Streaming is making an initial upfront cash investment of US$0.6 million, with additional milestone payments of US$0.75 million to be paid over the term of the Stream Agreement. Impact Highlights: The Project is expected to reduce biomass waste and prevent the associated release of carbon dioxide and methane emissions into the atmosphere equivalent to an estimated 6,500 tCO2e per year. It is anticipated that the majority of biochar generated by the Project will be used in agricultural applications to deliver soil enhancement through increased water and nutrient retention and ammonia reduction. The production process generates clean energy that reduces reliance on traditional lower efficiency sources and offers cost savings that contribute to increased community employment. The Project is expected to be a significant employer in the local community. Closing of the Stream Agreement is subject to customary conditions with closing anticipated to occur within a week.

07:46 EDT Wave Life Sciences announces anticipated 2022 milestones - WVE-004 for C9-ALS and C9-FTD: Additional single and multidose clinical data for WVE-004 expected throughout 2022. Wave expects to use these data to optimize WVE-004 dose level and frequency, as well as to enable discussions with regulatory authorities regarding the next phase of development later in 2022. Planning underway to initiate an open-label extension clinical trial in mid-2022. WVE-003 for HD: Clinical data expected in 2022 for WVE-003 to provide further insight into the clinical effects of PN chemistry and enable decision-making for this program. WVE-N531 for DMD: Clinical data, including muscle biopsies, expected in 2022 for WVE-N531 to provide further insight into the clinical effects of PN chemistry and enable decision-making for this program. AIMer GalNAc-conjugated program for AATD: Wave expects to select an AATD AIMer development candidate and initiate IND-enabling toxicology studies in the third quarter of 2022.

07:44 EDT Archer Aviation sees Q2 GAAP total operating expenses $80M-$86M - Non-GAAP total operating expenses of $47 million to $53 million; This reflects expected stock-based compensation, warrant expense and other one time expenses of approximately $33 million.

07:42 EDT BridgeBio announces license agreement with Bristol-Myers for BBP-398 - BridgeBio Pharma (BBIO) announced an exclusive license with Bristol Myers Squibb (BMY) to develop and commercialize BBP-398, a potentially best-in-class SHP2 inhibitor, in oncology. Under the terms of the agreement, BridgeBio will receive an upfront payment of $90M, up to $815M in development, regulatory and sales milestone payments, and tiered royalties in the low- to mid-teens. BridgeBio will retain the option to acquire higher royalties in the United States in connection with funding a portion of development costs upon the initiation of registrational studies. Based on the terms of the agreement, BridgeBio will continue to lead its ongoing Phase 1 monotherapy and combination therapy trials. Bristol Myers Squibb will lead and fund all other development and commercial activities. "We are grateful to be expanding our collaboration with Bristol Myers Squibb, a leader in oncology, and we believe this agreement will allow us to reach even more patients with difficult-to-treat cancers. We believe our SHP2 inhibitor has the potential to be a best-in-class agent given the data we have seen, and we are eager to see our monotherapy and combination trials progress in collaboration with our partners at Bristol Myers Squibb," said Neil Kumar, Ph.D., founder and CEO of BridgeBio.

07:39 EDT NFI Group unit receives order from MTD for 9 battery electric buses - NFI Group announced that its subsidiary New Flyer of America Inc. has received two new contracts from Santa Barbara Metropolitan Transit District for a total of nine battery-electric, zero-emission Xcelsior CHARGE forty-foot heavy-duty transit buses. "Today, MTD joins ten California transit agencies in choosing battery-electric buses from New Flyer to power their transition to zero-emission mobility," said Chris Stoddart, President, North American Bus and Coach, NFI. "Built on the proven Xcelsior platform, our battery-electric buses deliver immediate clean air benefits by reducing up to 160 tons of greenhouse gas emissions per year. Together with MTD, we are mitigating climate change and building more sustainable communities in California."

07:38 EDT Titan Medical reports cash, cash equivalents of $30.1M as of March 31 - "The entire team is focused on driving performance and progress supporting our IDE application submission milestone. We are also starting to prepare for the forthcoming commercialization of the Enos single-access RAS platform for gynecological surgery, our initial target indication for use," stated Paul Cataford, Interim President, CEO and Board Chair. "We are working closely with Benchmark on the capital equipment build of six Enos systems and have expanded our team and capability for our in-house production of instruments and cameras at our Chapel Hill facility. These capital units, instruments and cameras will go into validation and verification testing in late summer," concluded Mr. Cataford. The company remains on track with the De Novo regulatory process for marketing authorization with the U.S. Food and Drug Administration. Utilizing the Q-Submission Program, the company has engaged in ongoing dialogue with the FDA clarifying requirements in an effort to mitigate against timeline risks. The company plans to file the IDE application with the FDA in the first quarter of 2023 and anticipates receiving a response on the IDE from the FDA in the first half of 2023. Following IDE approval, Titan expects the IDE clinical study to proceed and be completed in time for submission of a De Novo classification request in 2024. Commercial launch of the Enos system is scheduled to begin upon receipt of marketing authorization from the FDA, anticipated in early 2025.

07:37 EDT Tilray announces expansion of Good Supply's cannabis portfolio - Tilray Brands announced the expansion of Good Supply's cannabis portfolio with the launch of new high-potency products including liquid wax vapes and exclusive new flower strains that will be available in select markets across Canada.

07:34 EDT Stealth Biotherapeutics granted FDA orphan designation for elamipretide - Stealth BioTherapeutics announced that the U.S. FDA Office of Orphan Products Development has granted Orphan Drug Designation to elamipretide for the treatment of patients with Duchenne muscular dystrophy. The company also announced that the FDA's Division of Neurology I has granted its request for a pre-IND meeting to discuss a development path for elamipretide in combination with products within the approved therapeutic class of exon-skipping phosphorodiamidate morpholino oligomers. The company has previously presented data demonstrating that administration of elamipretide in combination with a PMO significantly improves dystrophin expression levels in the X-linked muscular dystrophy mouse model. The company also previously conducted a pre-IND meeting with the FDA's Division of Cardiology and Nephrology during which it aligned on a potential development path for elamipretide for cardiomyopathy associated with DMD.

07:33 EDT Decibel Therapeutics expects cash to fund operations into 2024 - Based on its current operating and development plans, Decibel believes that its existing cash, cash equivalents and available-for-sale securities will fund its pipeline programs and operating expenses into 2024.

07:33 EDT Kelly Services raises quarterly dividend 50% to 7.5c per share - On May 10, its board of directors declared an increased dividend of 7.5c per share. The dividend is payable June 9 to shareholders of record as of the close of business on May 26, and represents a 50% increase. Commenting on the dividend increase, CEO Quigley said, "We are pleased that our improving operating results and strategic progress have given us the ability to return our dividend back to pre-pandemic levels and enhance shareholder value."

07:32 EDT MediWound announces results from US Phase 2 trial of EscharEx - MediWound announced positive results from its U.S. Phase 2 clinical study of EscharEx for the debridement of venous leg ulcers, VLUs. The study met its primary endpoint, its key secondary endpoints with high degree of statistical significance, as well as its wound closure safety measurements. MediWound anticipates meeting with the U.S. Food and Drug Administration, FDA, in the second half of 2022, for an End-of-Phase 2 meeting to discuss study results and a potential Phase 3 pivotal plan for EscharEx. U.S. key opinion leaders will join MediWound management in its coming earning call on May 17 at 8:30am EDT to discuss the data. The study met its primary endpoint with a high degree of statistical significance, demonstrating that patients treated with EscharEx had a statistically significant higher incidence of complete debridement during the 14-day measurement period within up to 8 applications compared to gel vehicle vs. gel vehicle: 30%. EscharEx efficacy superiority remained statistically significant compared to gel vehicle after adjusting for pre-specified covariates ascribed to patient baseline characteristics, wound size, wound age and regions. The study met key secondary and exploratory endpoints. Patients treated with EscharEx had a statistically significant higher incidence of complete debridement, during the same 14-day measurement period, compared to patients treated by non-surgical standard-of-care and the time to achieve complete debridement was significantly shorter. Estimated median time to complete debridement, was 9 days for patients treated with EscharEx and 59 days for patients treated with NSSOC. On average, complete debridement was achieved after 3.6 applications of EscharEx compared to 12.8 applications with NSSOC. Patients treated with EscharEx demonstrated significantly higher incidence of at least 75% granulation tissue at the end of the treatment period compared to gel vehicle. Favorable trends were observed in wound area reduction and reduction of pain compared to gel vehicle. In addition, the study showed that EscharEx was safe and well tolerated, and the overall safety was comparable between the arms as assessed by the data safety monitoring board. Importantly, there were no observed deleterious effects on wound closure and no material differences in reported adverse events.

07:30 EDT Bunge boosts quarterly dividend 19% to 62.5c per share - Bunge Limited announced that its Board of Directors has declared a10c, or 19%, increase in the regular quarterly cash dividend to 62.5c per common share. The dividend is payable on September 2 to shareholders of record on August 19.

07:27 EDT Cyxtera Technologies expands to India via partnership with Sify Technologies - Cyxtera (CYXT) announced it will begin offering colocation solutions in India through a strategic partnership with Sify Technologies (SIFY). Cyxtera can now provide colocation services to customers in five additional markets in one of the most important and fastest growing global economies. As part of the partnership, Sify will also resell Cyxtera's full suite of solutions across markets in North America, Europe, and Asia Pacific to its more than 10,000 customers. Cyxtera customers will now be able to leverage infrastructure solutions for their hybrid IT needs in Sify's carrier-neutral facilities in Mumbai, Noida, Chennai, Hyderabad, and Kolkata. As an official Cyxtera Channel Partner, Sify will be able to resell all Cyxtera services across the company's footprint in North America, Europe, and APAC. Sify customers will now have access to Cyxtera's colocation and interconnection solutions across more than 20 top-tier global markets, as well as the company's Enterprise Bare Metal and SmartCabs offerings. These customers will also have access to Cyxtera's intelligently automated, deeply connected data center fabric - the Digital Exchange - that allows companies to deploy every piece of their IT infrastructure on-demand and provides the foundation they need to modernize their operations to compete in today's digital world.

07:26 EDT Optinose sees FY XHANCE net revenues at least $90M - The company expects XHANCE net revenues for the full year of 2022 to be at least $90 million. In addition, the company expects full year 2022 XHANCE average net revenue per prescription to be at least $220. Previously the company expected full year 2022 XHANCE average net revenue per prescription to be at least $210. The company expects total GAAP operating expenses for 2022 to be in the range of $135 - $140 million, of which the company expects stock-based compensation to be approximately $10 million. The company expects top-line results from ReOpen2, the second its two clinical trials evaluating XHANCE as a potential treatment for chronic sinusitis, in June 2022.

07:25 EDT Vigil Neuroscience on track to report VGL101 Phase 1 data in 2H - The Company is on track to report VGL101 Phase 1 topline data and initiate a Phase 2 proof-of-concept trial in ALSP patients in the second half of 2022: Vigil completed dosing of the 20 mg/kg single ascending dose cohort without any safety signals and is currently dosing the 20 mg/kg multiple ascending dose cohort in its Phase 1 trial of VGL101, an investigational, fully human monoclonal antibody TREM2 agonist, in healthy volunteers. Vigil continues to engage with the Food and Drug Administration regarding the partial clinical hold at doses above 20 mg/kg. Accordingly, Vigil submitted data to the FDA from a 6-month GLP toxicology study in nonhuman primates in which there were no observed adverse findings and Phase 1 SAD clinical data. Vigil remains on track to initiate the Phase 2 proof-of-concept trial in the second half of 2022 and believes that 20 mg/kg is a clinically-relevant dose in ALSP. The Company continues to expect to initiate a Phase 1b trial of VGL101 for Alzheimer's disease (AD) in the second half of 2022: Vigil plans to initiate a Phase 1b biomarker-based clinical trial with VGL101 in genetically defined populations of AD patients with or without the relevant TREM2 variants.

07:21 EDT Latham Group announces $100M share repurchase program - On May 10, 2022, the company approved a stock repurchase program, which authorized the company to repurchase up to $100M of its shares of Common Stock over the next three years.

07:19 EDT Tuesday Morning sees FY22 adjusted EBITDA loss ($29M)-($26M) - Given the sales shortfall in the third quarter fiscal 2022 and the projected decrease in the fourth quarter fiscal 2022 coupled with increased markdowns required in the fourth quarter fiscal 2022, the company now expects to report an Adjusted EBITDA loss for fiscal 2022 between $26 million and $29 million. The company also continues to expect to maintain sufficient liquidity to cover its obligations and operating plans for the next twelve months.

07:15 EDT Entrada Therapeutics sees cash, equivalents funding operations into 2H24 - Cash, cash equivalents and marketable securities were $263.9M as of March 31, 2022, compared to $291.1M as of December 31, 2021. Based on current operating plans, Entrada expects its existing cash, cash equivalents and marketable securities will enable the company to fund its operating expenses and capital expenditure requirements into the second half of 2024.

07:11 EDT Shattuck Labs sees cash, equivalents funding operations into 2H24 - Shattuck believes its cash and cash equivalents and short-term investments will be sufficient to fund its operations into the second half of 2024, beyond results from its Phase 1 clinical trials of SL-172154 and SL-279252. This cash runway guidance is based on the company's current operational plans and excludes any additional funding that may be received or business development or additional clinical development activities that may be undertaken.

07:10 EDT Bio-Techne and Nonagen Bioscience enter supply agreement for bladder cancer test - Bio-Techne and Nonagen Bioscience announced an agreement for R&D Systems, a Bio-Techne brand, to exclusively manufacture Nonagen Bioscience's Oncuria bladder cancer diagnostic panel using xMAP Luminex technology. Oncuria is the first-of-its-kind multiplex protein-based urine test to provide early and accurate detection, therapy choice, and disease monitoring of bladder cancer. The Luminex-based multiplex assay panel combines Bio-Techne's high-quality reagents and over 40 years of industry-leading immunoassay experience with Nonagen's diagnostic expertise to create a powerful solution to advance bladder cancer treatment strategies. The partnership demonstrates Bio-Techne's commitment to supporting laboratory developed tests to bring clinical diagnostic tools to the market. Nonagen Bioscience and Bio-Techne are targeting 4Q22 to make Oncuria available as an LDT. The FDA granted Oncuria a Breakthrough Device Designation in September 2021, for predicting response to Bacillus Calmette-Guerin therapy, a first-line treatment for bladder cancer. The designation enables close collaboration with, and expedited review of the assay by the FDA. It also provides formal acknowledgement of Oncuria's utility and potential clinical benefit.

07:08 EDT Orchard Therapeutics sees cash, equivalents funding operations into 2024

07:07 EDT Amprius Technologies to go public via merger with Kensington Capital - Amprius Technologies and Kensington Capital Acquisition Corp. IV announced a definitive agreement for a business combination that would result in Amprius becoming a publicly-listed company. Upon closing of the transaction, the combined company will be named Amprius Technologies and its common stock will trade on the NYSE under the new ticker symbol "AMPX." Founded in 2008, Amprius develops, manufactures, and sells ultra-high energy density lithium-ion batteries using its innovative, patent-protected silicon nanowire anode technology. The business combination values Amprius at an implied pro forma enterprise value of $939M, assuming no redemptions by our public stockholders in connection with closing and the payment of estimated transaction expenses. The boards of directors of both Kensington and Amprius have approved the proposed transaction, which is expected to be completed in the second half of 2022, subject to, among other things, the approval by Kensington's stockholders and satisfaction or waiver of other conditions stated in the definitive documentation. The transaction will result in gross proceeds of approximately $430M to Amprius, comprised of $230M of cash held in Kensington's trust, before redemptions, and up to $200M in additional equity financing to be raised prior to the closing of the business combination.

07:04 EDT Sharecare announces $50M share repurchase program

07:00 EDT Bristol-Myers reports POETYK PSO long-term extension trial results - Bristol Myers Squibb announced two-year results from the POETYK PSO long-term extension trial demonstrating durable efficacy and a consistent safety profile with deucravacitinib treatment in adult patients with moderate to severe plaque psoriasis. Clinical efficacy was maintained through up to two years of deucravacitinib treatment, with response rates at Week 60 in the LTE of 77.7% and 58.7% for Psoriasis Area and Severity Index 75 and static Physicians Global Assessment 0/1, respectively, the company reported. The overall safety profile of deucravacitinib observed through two years spans 2,482 patient years of treatment and was consistent with that observed in the previously presented pivotal Phase 3 POETYK PSO-1 and POETYK PSO-2 trials. These data are being presented at the European Academy of Dermatology and Venereology, or EADV, Spring Symposium, taking place May 12-14.

06:58 EDT BD announces U.S. launch of infectious disease molecular diagnostics platform - BD announced the U.S. launch of its new, fully automated, high-throughput infectious disease molecular diagnostics platform. With 510(k) clearance from the U.S. Food and Drug Administration, the new BD COR MX instrument is a new analytic instrument option for the BD COR System. The first test available on the new system is the BD CTGCTV2 molecular assay, a single test that detects the three most prevalent non-viral sexually transmitted infections - Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis. These three STIs can include a range of negative patient outcomes, from pregnancy complications to increased risk of HIV. The BD COR MX/PX System integrates and automates the complete molecular laboratory workflow, from sample processing to diagnostic test result for large, high-throughput labs. The BD COR System eliminates the need to sort specimens enabling the lab tech to have very little interaction with the specimen freeing up time for other critical lab processes. Together, the BD COR MX/PX System allows 1,700 specimens to be loaded, with onboard capacity for reagents and samples that provide more than seven hours of unimpeded system processing. The system is capable of delivering up to 1,000 sample results in 24 hours, eliminating multiple manual interactions per shift that were traditionally required. It also offers dual DNA targets for CT and GC detection together in the same sample and assay, which can help reduce false positives.

06:56 EDT BiondVax provides update on NanoAbs program at Biomed conference - BiondVax Pharmaceuticals announced that Dr. Tamar Ben-Yedidia, BiondVax's Chief Scientific Officer, today presented BiondVax's progress, achieving certain milestones, under its nanosized antibodies program. Dr. Ben Yedidia today presented at the Biomed conference in Tel Aviv, Israel and the associated presentation will be accessible from the Company's investor relations website. The main highlights of the progress are summarized below. The NanoAb program, in collaboration with the Max Planck Institute for Multidisciplinary Sciences and University Medical Center Gottingen, Germany, aims to address diseases with large unmet medical needs and attractive commercial opportunities, such as COVID-19, asthma, psoriasis, psoriatic arthritis, and macular degeneration. Summary of Recent Achievements Successful technology transfer from Max Planck to BiondVax' manufacturing facility in Jerusalem was demonstrated. Upon testing, it was shown that BiondVax was able to successfully manufacture its first exclusively licensed NanoAb for the treatment of COVID-19 and demonstrated strong in-vitro COVID-19 neutralization capability at levels similar to those demonstrated by NanoAbs originally produced at Max Planck. Those NanoAbs produced at BiondVax's facility demonstrated similarly strong COVID-19 in-vitro neutralization capacity also after being sprayed through a medical device inhaler that is expected to be used in the first in-human clinical trials planned for 2023. A new NanoAb targeting Omicron, that was generated by Max Planck, has recently been shown to successfully neutralize the Omicron variant of COVID-19, in-vitro. This NanoAb is expected to be manufactured and used in BiondVax's first in-human trials.

06:54 EDT Tapestry approves new $1.5B share repurchase program - Tapestry-s Board has approved a new $1.5B share repurchase program. The company now forecasts the repurchase of $1.6B in common stock in FY22, an increase of $350M from the prior outlook of $1.25B. In Q3, the company deployed $500M to buy back approximately 13 million shares of its common stock at an average cost of $37.06 per share. As of quarter-end, $350M remained on the existing authorization, which is intended to be utilized in Q4. In addition, there is $1.5B available under the newly announced authorization, which the company expects to begin utilizing in FY23.

06:53 EDT Quarterhill appoints Andrew Parolin as CEO of WiLAN - Quarterhill announces that Andrew Parolin has been appointed CEO of Wi-LAN, its wholly owned patent licensing business. Mr. Parolin has been with WiLAN for 15 years and a key member of the executive team during that time. Most recently he was Senior Vice-President, Licensing, responsible for the licensing of the company's portfolio of wireless, wireline, digital television and other technologies.

06:51 EDT Crescent Point Energy raises quarterly dividend by over 40% to 6.5c per share - Crescent Point said: "Given its continued execution and the recent strength in commodity prices, the Company now expects to attain its near-term net debt target of approximately $1.3 billion during third quarter 2022. Consistent with Crescent Point's focus on returning capital to shareholders, the Board of Directors has approved and declared a second quarter 2022 dividend increase to $0.065 per share to be paid on July 4, 2022 to shareholders of record on June 15, 2022. This equates to an annualized dividend of $0.26 per share, representing an increase of over 40 percent from the prior level. The Company's dividend policy and payout ratio is based on a framework that targets dividend sustainability at lower commodity prices, allows for flexibility in its capital allocation process and the potential for dividend growth over time. Since initiating its planned share repurchases in December 2021, Crescent Point has repurchased for cancellation approximately 13.5 million shares to-date for total consideration of approximately $110 million. This includes approximately 7.3 million shares repurchased during first quarter 2022 for total consideration of approximately $62 million. The Company is on track to execute the remainder of its previously announced share repurchase plan of up to $150 million by mid-2022. Crescent Point plans to revisit its budget for share repurchases for the second half of the year as part of an updated return of capital framework. The Company has approval to repurchase, for cancellation, up to 10 percent of its public float under its normal course issuer bid, which expires on March 8, 2023."

06:46 EDT US Foods reaffirms FY22 guidance provided on February 17

06:40 EDT XP Inc. to create digital assets trading platform in collaboration with Nasdaq - XP Inc. (XP) announced the creation of XTAGE, a new trading platform for digital assets in collaboration with Nasdaq (NDAQ). XTAGE represents a key milestone in democratizing access to the digital assets market in Brazil. Built on Nasdaq's leading trading technology, XP's platform is uniquely positioned to flexibly scale as it grows and introduces new products and services. The platform is expected to be operational by the end of the second quarter of 2022.

06:35 EDT Matinas BioPharma sees Q2 adjusted EBITDA $4M-$6M - Sees Q2 ex-TAC gross profit $59M-$62M.

06:25 EDT IRIS.TV enters partnership with Publica to integrate contextual data - IRIS.TV has announced a new partnership with Publica to integrate video-level contextual data into Publica's CTV Ad Server. The new partnership will allow publishers to use their IRIS-enabled data partner segments for forecasting and targeting in the Publica user interface, improving the outcomes for CTV advertisers when running ads within their ad breaks.

06:16 EDT PureCycle Technologies reports liquidity of $609.9M - The Company had total liquidity of $609.9 million including $418.0 million of cash, cash equivalents and debt securities available for sale and $191.9 million in restricted cash. PureCycle had $255.7 million in debt and accrued interest, less $16.8 million of discount and issuance costs as of March 31, 2022. PureCycle's Ironton flagship purification facility's original budget was $242.1 million, which was funded through bond financing. The Company currently expects to exceed the original budget by $55 - $65 million due to increased investments as well as growing inflationary pressures.

06:14 EDT PureCycle Technologies CEO says 'made considerable operational progress' in Q1 - Mike Otworth, PureCycle's Chairman and CEO said, "PureCycle made considerable operational progress during the first quarter of 2022 and continues to execute against its strategic growth plan. Our Augusta purification facility build-out is underway and remains on track for startup in the fourth quarter of 2023. We continue to expand our feedstock supply network highlighted by significant progress on our first two lines in Augusta, while the successful commercial market progress of our team is visible through the full allocation of Ironton and 70% allocation of the first two lines in Augusta through multi-year commitments. PureCycle remains steadfast in our mission to advance the sustainable plastic revolution through our unique purification process. We are excited about our recent progress and look forward to updating you as we continue to advance our objectives throughout the remainder of 2022 and beyond."

06:13 EDT Ferguson announces primary listing now on NYSE - Ferguson announces that its primary listing is now on the New York Stock Exchange. This follows the transfer of the company's listing category on the Official List of the Financial Conduct Authority from "Premium Listing" to "Standard Listing" as of 0800hrs GMT/0300hrs ET on May 12. Ferguson's shares remain eligible for and continue to trade on the Main Market of the London Stock Exchange as a Standard Listing segment issuer.

06:09 EDT Cazoo launches service in Spain - Cazoo announced that it has now launched its service in Spain, delivering better selection, value, transparency, convenience and peace of mind to Spanish consumers when buying their next car.

06:04 EDT Squarespace board authorizes $200M share repurchase program - Squarespace's board of directors authorized a general share repurchase program of the Company's Class A common stock of up to $200 million with no fixed expiration. These repurchases may occur in the open market, through privately negotiated transactions, through block purchases, other purchase techniques or by any combination of such methods. The timing and actual amount of shares repurchased will depend on a variety of different factors and may be modified, suspended or terminated at any time at the discretion of the board of directors.

05:58 EDT Qualtrics to go live on Amazon Web Services Cloud Infrastructure in the UK - Qualtrics (XM) announced it will go live on Amazon Web Services (AMZN) Cloud Infrastructure in London in the second half of 2022. Qualtrics customers will be able to access the Qualtrics XM/OS platform locally via the AWS London Region. The company will also open a new office and customer experience centre in London. These investments come as organisations are increasingly turning to Qualtrics to help them deliver customer, employee, brand and product experiences that create meaningful connections.

05:43 EDT Instacart announces confidential submission of draft registration statement - Instacart announced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission. The registration statement is expected to become effective after the SEC completes its review process, subject to market and other conditions. Instacart competes with with offerings from Amazon (AMZN), Uber (UBER) and DoorDash (DASH).